Cargando…

Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus

[Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Bello, Fabio, Bonifazi, Alessandro, Giorgioni, Gianfabio, Piergentili, Alessandro, Sabbieti, Maria Giovanna, Agas, Dimitrios, Dell’Aera, Marzia, Matucci, Rosanna, Górecki, Marcin, Pescitelli, Gennaro, Vistoli, Giulio, Quaglia, Wilma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007111/
https://www.ncbi.nlm.nih.gov/pubmed/32374602
http://dx.doi.org/10.1021/acs.jmedchem.9b02100
_version_ 1783672431308701696
author Del Bello, Fabio
Bonifazi, Alessandro
Giorgioni, Gianfabio
Piergentili, Alessandro
Sabbieti, Maria Giovanna
Agas, Dimitrios
Dell’Aera, Marzia
Matucci, Rosanna
Górecki, Marcin
Pescitelli, Gennaro
Vistoli, Giulio
Quaglia, Wilma
author_facet Del Bello, Fabio
Bonifazi, Alessandro
Giorgioni, Gianfabio
Piergentili, Alessandro
Sabbieti, Maria Giovanna
Agas, Dimitrios
Dell’Aera, Marzia
Matucci, Rosanna
Górecki, Marcin
Pescitelli, Gennaro
Vistoli, Giulio
Quaglia, Wilma
author_sort Del Bello, Fabio
collection PubMed
description [Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2-position and the cyclohexyl moiety in the 6-position, showed pK(i) values for mAChRs higher than those of 2 and a selectivity profile analogous to that of the clinically approved drug oxybutynin. The study of the enantiomers of 3b and the corresponding tertiary amine 33b revealed that the eutomers are (2S,6S)-(−)-3b and (2S,6S)-(−)-33b, respectively. Docking simulations on the M(3) mAChR-resolved structure rationalized the experimental observations. The quaternary ammonium function, which should prevent the crossing of the blood–brain barrier, and the high M(3)/M(2) selectivity, which might limit cardiovascular side effects, make 3b a valuable starting point for the design of novel antagonists potentially useful in peripheral diseases in which M(3) receptors are involved.
format Online
Article
Text
id pubmed-8007111
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-80071112021-03-30 Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus Del Bello, Fabio Bonifazi, Alessandro Giorgioni, Gianfabio Piergentili, Alessandro Sabbieti, Maria Giovanna Agas, Dimitrios Dell’Aera, Marzia Matucci, Rosanna Górecki, Marcin Pescitelli, Gennaro Vistoli, Giulio Quaglia, Wilma J Med Chem [Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2-position and the cyclohexyl moiety in the 6-position, showed pK(i) values for mAChRs higher than those of 2 and a selectivity profile analogous to that of the clinically approved drug oxybutynin. The study of the enantiomers of 3b and the corresponding tertiary amine 33b revealed that the eutomers are (2S,6S)-(−)-3b and (2S,6S)-(−)-33b, respectively. Docking simulations on the M(3) mAChR-resolved structure rationalized the experimental observations. The quaternary ammonium function, which should prevent the crossing of the blood–brain barrier, and the high M(3)/M(2) selectivity, which might limit cardiovascular side effects, make 3b a valuable starting point for the design of novel antagonists potentially useful in peripheral diseases in which M(3) receptors are involved. American Chemical Society 2020-05-06 2020-06-11 /pmc/articles/PMC8007111/ /pubmed/32374602 http://dx.doi.org/10.1021/acs.jmedchem.9b02100 Text en Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Del Bello, Fabio
Bonifazi, Alessandro
Giorgioni, Gianfabio
Piergentili, Alessandro
Sabbieti, Maria Giovanna
Agas, Dimitrios
Dell’Aera, Marzia
Matucci, Rosanna
Górecki, Marcin
Pescitelli, Gennaro
Vistoli, Giulio
Quaglia, Wilma
Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title_full Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title_fullStr Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title_full_unstemmed Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title_short Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
title_sort novel potent muscarinic receptor antagonists: investigation on the nature of lipophilic substituents in the 5- and/or 6-positions of the 1,4-dioxane nucleus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007111/
https://www.ncbi.nlm.nih.gov/pubmed/32374602
http://dx.doi.org/10.1021/acs.jmedchem.9b02100
work_keys_str_mv AT delbellofabio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT bonifazialessandro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT giorgionigianfabio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT piergentilialessandro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT sabbietimariagiovanna novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT agasdimitrios novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT dellaeramarzia novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT matuccirosanna novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT goreckimarcin novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT pescitelligennaro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT vistoligiulio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus
AT quagliawilma novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus